|
[1] CHEN CL,MAO H. The potential application of proton pump inhibitors in cirrhosis[J]. Chin Hepatol,2010,15(6):470-472.(in Chinese)陈春林，毛华．质子泵抑制剂在肝硬化治疗中的应用可能性[J]．肝脏，2010,15(6):470-472.
|
|
[2] Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association; Chinese Society of Endoscopy,Chinese Medical Association. Guidelines for the diagnosis and treatment of esophageal and gastric variceal bleeding in cirrhotic portal hypertension[J]. J Clin Hepatol,2016,32(2):203-217.(in Chinese)中华医学会肝病学分会，中华医学会消化病学分会，中华医学会内镜学分会．肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]．临床肝胆病杂志，2016,32(2):203-219.
|
|
[3] Chinese Society of Hepatology,Chinese Medical Association.Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol,2019,35(11):2408-2425.(in Chinese)中华医学会肝病学分会．肝硬化诊治指南[J]．临床肝胆病杂志，2019,35(11):2408-2425.
|
|
[4] DAM G,VILSTRUP H,WATSON H,et al. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites[J]. Hepatology,2016,64(4):1265-1272.
|
|
[5] MACLAREN R,REYNOLDS PM,ALLEN RR. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit[J]. JAMA Intern Med,2014,174(4):564-574.
|
|
[6] DULTZ G,PIIPER A,ZEUZEM S,et al. Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis[J]. Aliment Pharmacol Ther,2015,41(5):459-466.
|
|
[7] COLE HL,PENNYCOOK S,HAYES PC. The impact of proton pump inhibitor therapy on patients with liver disease[J]. Aliment Pharmacol Ther,2016,44(11-12):1213-1223.
|
|
[8] STANLEY AJ,LAINE L. Management of acute upper gastrointestinal bleeding[J]. BMJ,2019,364:l536.
|
|
[9] SREEDHARAN A,MARTIN J,LEONTIADIS GI,et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding[J]. Cochrane Database Syst Rev,2010,7:CD005415.
|
|
[10] LIN L,CUI B,DENG Y,et al. The efficacy of proton pump inhibitor in cirrhotics with variceal bleeding:A systemic review and Meta-analysis[J]. Digestion,2020.[Online ahead of print]
|
|
[11] TAKEUCHI Y,KITANO S,BANDOH T,et al. Acceleration of gastric ulcer healing by omeprazole in portal hypertensive rats. Is its action mediated by gastrin release and the stimulation of epithelial proliferation?[J]. Eur Surg Res,2003,35(2):75-80.
|
|
[12] ARDEVOL A,IBANEZ-SANZ G,PROFITOS J,et al. Survival of patients with cirrhosis and acute peptic ulcer bleeding compared with variceal bleeding using current first-line therapies[J]. Hepatology,2018,67(4):1458-1471.
|
|
[13] BAJAJ JS,ZADVORNOVA Y,HEUMAN DM,et al. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites[J]. Am J Gastroenterol,2009,104(5):1130-1134.
|
|
[14] YAMAMOTO K,ISHIGAMI M,HONDA T,et al. Influence of proton pump inhibitors on microbiota in chronic liver disease patients[J]. Hepatol Int,2019,13(2):234-244.
|
|
[15] DAM G,VILSTRUP H,ANDERSEN PK,et al. Effect of proton pump inhibitors on the risk and prognosis of infections in patients with cirrhosis and ascites[J]. Liver Int,2019,39(3):514-521.
|
|
[16] LIN L,HOU L,DENG Y,et al. Acid suppression therapy and its association with spontaneous bacterial peritonitis incidence:A systemic review and meta-analysis[J]. Hepatol Res,2020,50(2):233-245.
|
|
[17] TERG R,CASCIATO P,GARBE C,et al. Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis:A multicenter prospective study[J]. J Hepatol,2015,62(5):1056-1060.
|
|
[18] CAMPBELL MS,OBSTEIN K,REDDY KR,et al. Association between proton pump inhibitor use and spontaneous bacterial peritonitis[J]. Dig Dis Sci,2008,53(2):394-398.
|
|
[19] ZHU J,QI X,YU H,et al. Association of proton pump inhibitors with the risk of hepatic encephalopathy during hospitalization for liver cirrhosis[J]. United European Gastroenterol J,2018,6(8):1179-1187.
|
|
[20] KUAN YC,HUANG KW,LIN CL,et al. Short-term proton pump inhibitor use and hepatic encephalopathy risk in patients with decompensated cirrhosis[J]. J Clin Med,2019,8(8):1108.
|
|
[21] LEWIS DS,LEE TH,KONANUR M,et al. Proton pump inhibitor use is associated with an increased frequency of new or worsening hepatic encephalopathy after transjugular intrahepatic portosystemic shunt creation[J]. J Vasc Interv Radiol,2019,30(2):163-169.
|
|
[22] SHI D,ZHOU Z,DAI Y,et al. Proton pump inhibitor therapy and hepatic encephalopathy risk in cirrhotic patients:A systematic review with meta-analysis[J]. Clin Drug Investig,2019,39(9):847-856.
|
|
[23] TARANTINO G,CONCA P,BASILE V,et al. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease[J]. Hepatol Res,2007,37(6):410-415.
|
|
[24] SHAO YJ,CHAN TS,TSAI K,et al. Association between proton pump inhibitors and the risk of hepatocellular carcinoma[J]. Aliment Pharmacol Ther,2018,48(4):460-468.
|
|
[25] NAKATAKE R,HISHIKAWA H,KOTSUKA M,et al. The proton pump inhibitor lansoprazole has hepatoprotective effects in in vitro and in vivo rat models of acute liver injury[J]. Dig Dis Sci,2019,64(10):2854-2866.
|
|
[26] KAO WY,SU CW,CHIA-HUI TAN E,et al. Proton pump inhibitors and risk of hepatocellular carcinoma in patients with chronic hepatitis B or C[J]. Hepatology,2019,69(3):1151-1164.
|
|
[27] SONG HJ,JIANG X,HENRY L,et al. Proton pump inhibitors and risk of liver cancer and mortality in patients with chronic liver disease:A systematic review and meta-analysis[J]. Eur J Clin Pharmacol,2020,76(6):851-866.
|
|
[28] WANG J,WU Y,BI Q,et al. Adverse outcomes of proton pump inhibitors in chronic liver disease:A systematic review and meta-analysis[J]. Hepatol Int,2020,14(3):385-398.
|
|
[29] STADLBAUER V,KOMAROVA I,KLYMIUK I,et al. Disease severity and proton pump inhibitor use impact strongest on faecal microbiome composition in liver cirrhosis[J]. Liver Int,2020,40(4):866-877.
|
|
[30] WOODHOUSE CA,PATEL VC,SINGANAYAGAM A,et al.Review article:The gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease[J].Aliment Pharmacol Ther,2018,47(2):192-202.
|
|
[31] ZHERNAKOVA A,KURILSHIKOV A,BONDER MJ,et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity[J]. Science,2016,352(6285):565-569.
|
|
[32] LI Z,ZHANG W,JIA L,et al. Advances in the clinical application of high-throughput sequencing in detecting microbiota in cirrhotic ascites,serum,and feces[J]. J Clin Hepatol,2020,36(4):900-903.(in Chinese)李真，张维，贾琳，等．高通量测序在肝硬化患者腹水、血清及粪便微生物群检测中的应用[J]．临床肝胆病杂志，2020,36(4):900-903.
|
|
[33] HATTON G,SHAWCROSS DL. Is treating the gut microbiome the key to achieving better outcomes in cirrhosis?[J]. Expert Rev Gastroenterol Hepatol,2019,13(1):1-2.
|
|
[34] OKURA Y,NAMISAKI T,SATO S,et al. Proton pump inhibitor therapy does not increase serum endotoxin activity in patients with cirrhosis[J]. Hepatol Res,2019,49(2):232-238.
|
|
[35] SU T,LAI S,LEE A,et al. Meta-analysis:Proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth[J]. J Gastroenterol,2018,53(1):27-36.
|
|
[36] FRANCO DL,DISBROW MB,KAHN A,et al. Duodenal aspirates for small intestine bacterial overgrowth:Yield,PPIs,and outcomes after treatment at a tertiary academic medical center[J]. Gastroenterol Res Pract,2015,2015:971582.
|
|
[37] JANKA T,TORNAI T,BORBELY B,et al. Deleterious effect of proton pump inhibitors on the disease course of cirrhosis[J].Eur J Gastroenterol Hepatol,2020,32(2):257-264.
|
DownLoad: